Abstract
Lamellarins are a large family of marine alkaloids with potential anticancer activity that have been isolated from diverse marine organisms, mainly ascidians and sponges. All lamellarins feature a 3,4-diarylpyrrole system. Pentacyclic lamellarins, whose polyheterocyclic system has a pyrrole core, are the most active compounds. Some of these alkaloids are potently cytotoxic to various tumor cell lines. To date, Lam-D and Lam-H have been identified as lead compounds for the inhibition of topoisomerase I and HIV-1 integrase, respectively — nuclear enzymes which are over-expressed in deregulation disorders. Moreover, these compounds have been reported for their efficacy in treatment of multi-drug resistant (MDR) tumors cells without mediated drug efflux, as well as their immunomodulatory activity and selectivity towards melanoma cell lines. This article is an overview of recent literature on lamellarins, encompassing their isolation, recent synthetic strategies for their total synthesis, the preparation of their analogs, studies on their mechanisms of action, and their structure-activity relationships (SAR).
Keywords: Lamellarins, marine alkaloids, nitrogen heterocycles, cytotoxic agents, topoisomerase I
Anti-Cancer Agents in Medicinal Chemistry
Title: Recent Advances in Lamellarin Alkaloids: Isolation, Synthesis and Activity
Volume: 8 Issue: 7
Author(s): D. Pla, F. Albericio and M. Alvarez
Affiliation:
Keywords: Lamellarins, marine alkaloids, nitrogen heterocycles, cytotoxic agents, topoisomerase I
Abstract: Lamellarins are a large family of marine alkaloids with potential anticancer activity that have been isolated from diverse marine organisms, mainly ascidians and sponges. All lamellarins feature a 3,4-diarylpyrrole system. Pentacyclic lamellarins, whose polyheterocyclic system has a pyrrole core, are the most active compounds. Some of these alkaloids are potently cytotoxic to various tumor cell lines. To date, Lam-D and Lam-H have been identified as lead compounds for the inhibition of topoisomerase I and HIV-1 integrase, respectively — nuclear enzymes which are over-expressed in deregulation disorders. Moreover, these compounds have been reported for their efficacy in treatment of multi-drug resistant (MDR) tumors cells without mediated drug efflux, as well as their immunomodulatory activity and selectivity towards melanoma cell lines. This article is an overview of recent literature on lamellarins, encompassing their isolation, recent synthetic strategies for their total synthesis, the preparation of their analogs, studies on their mechanisms of action, and their structure-activity relationships (SAR).
Export Options
About this article
Cite this article as:
Pla D., Albericio F. and Alvarez M., Recent Advances in Lamellarin Alkaloids: Isolation, Synthesis and Activity, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (7) . https://dx.doi.org/10.2174/187152008785914789
DOI https://dx.doi.org/10.2174/187152008785914789 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epigenetic Effects of Environmental Chemicals on Reproductive Biology
Current Drug Targets Graphical Abstracts
Letters in Drug Design & Discovery Analysis of Oxaliplatin Resistance in Colorectal Cancer Cells by Combined Proteomics and Phosphoproteomic
Current Proteomics Toxicity of Biodegradable Nanoscale Preparations
Current Drug Metabolism Host Pharmacogenetics in the Treatment of HIV and Cancer
Current Drug Safety CRISPR/Cas9 in Stem Cell Research: Current Application and Future Perspective
Current Stem Cell Research & Therapy The p35 Family of Apoptosis Inhibitors
Current Genomics Potential Therapeutic Agents Against Par-4 Target for Cancer Treatment: Where Are We Going?
Current Drug Targets DTCM-Glutarimide Hinders Growth of Childhood Leukemia Cells but Fails to Improve the Efficacy of Commonly Used Chemotherapeutic Agents
Current Bioactive Compounds Patent Selections
Recent Patents on Biomedical Engineering (Discontinued) Carbon Nanotubes: Materials for Medicinal Chemistry and Biotechnological Applications
Current Medicinal Chemistry Neurokinin-1 Receptor Antagonists in Lung Cancer Therapy
Letters in Drug Design & Discovery Protein Tyrosine Phosphatases, New Targets for Cancer Therapy
Current Cancer Drug Targets Recent Patents on the Use of Antioxidant Agents in Food
Recent Patents on Food, Nutrition & Agriculture Brain Drug Delivery Systems for the Stroke Intervention and Recovery
Current Pharmaceutical Design Nanotechnology for Nanomedicine and Delivery of Drugs
Current Pharmaceutical Design Nanoparticulated Polymeric Systems for Gene Delivery
Current Pharmaceutical Design Molecular Mechanisms of Epithelial Regeneration and Neovascularization During Healing of Gastric and Esophageal Ulcers
Current Medicinal Chemistry Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases
Anti-Cancer Agents in Medicinal Chemistry Ag+ Complexes as Potential Therapeutic Agents in Medicine and Pharmacy
Current Medicinal Chemistry